ADIENNE Pharma & Biotech Signs Service Agreement with Selexis for the Development of a Novel Fully Human Mini-Antibody
Geneva, Switzerland, May 15, 2012 (PRNewswire) – Selexis SA, a global life sciences company for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins, announced today that ADIENNE Pharma & Biotech has entered into a Service Agreement with Selexis for the rapid development of a manufacturing cell line for one of ADIENNE’s orphan drugs.
"We are very pleased that ADIENNE has chosen to use Selexis for the development of its molecule," said Igor Fisch, PhD, CEO of Selexis SA. “Combining our expertise in difficult-to-express proteins with our SUREtechnology Platform™ is an important step in advancing ADIENNE’s project to the clinic.”"Selexis expertise will be an added value for our molecule,” said Antonio Francesco Di Naro, PhD, Founder, and CEO of ADIENNE Pharma & Biotech. “This collaboration will be fruitful for our company.”
ADIENNE is a dynamic pharma and biotech company dedicated to the treatment of rare and severe diseases. It is located in Bergamo (Italy) and operates both in the European and in the International pharmaceutical market. ADIENNE’s mission is to satisfy unmet clinical needs. Within the frame of challenging and life-threatening clinical pathologies, the company develops biological orphan drugs products from research to commercialization in onco-haematology, autoimmune diseases, solid organ and bone marrow transplantation. ADIENNE is involved in biotechnology research and production, holding its own laboratories and manufacturing site, with fully integrated scientific, regulatory, pharmacovigilance, clinical, medical and commercial structures.
Web www.selexis.com
LinkedIn www.linkedin.com/company/selexis-sa
Twitter www.twitter.com/SelexisSA
Facebook www.facebook.com/SelexisSA
Contact details
-
- Sarah Martin-Tyrrell
-
KBI Biopharma Company Inquiries
Senior Manager, PR and Content - sarah.martin-tyrrell@crownbio.com
Related topics
Related news
KBI Biopharma to Lead Development and Manufacturing of Alanis Therapeutics’ Antagonistic Monoclonal Antibody Candidate
KBI Biopharma Selected as CDMO of Choice to Fast-Track Development of Pre-Clinical Antibody for Blood Cancers Using SUREmAbTM Technology
Following a Successful FDA Inspection, KBI Biopharma Extends and Expands Commercial Contract with Leading Global Phar...
Extension reinforces KBI’s commitment to forge long-term partnerships to successfully address complex clinical development and commercialization challenges.
KBI Biopharma Strengthens Quality and Regulatory Affairs Expertise with Appointment of Chief Quality Officer
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and cGMP contract development and manufacturing organization (CDMO), today announced the appointment of Peter Carbone as the new Chief Quality...
KBI Biopharma, Inc. and Argonaut Manufacturing Services, Inc. Forge Strategic Alliance to Support Global Biopharmaceu...
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and cGMP contract development and manufacturing organization (CDMO), and Argonaut Manufacturing Services, Inc. (Argonaut), a cGMP contract man...
KBI Biopharma, Inc. Expands Global Portfolio with Launch of SUREmAb™ for Faster Monoclonal Antibody Development and M...
KBI Biopharma, Inc. (KBI Biopharma), a JSR Life Sciences company, today announced the launch of SUREmAb™, an offering built on the robustness of KBI’s SUREtechnology Platform, that allows for optim...